AstraZeneca Forms an AI Deal in China; Third Harmonic Advances Liquidation Plans
7 Articles
7 Articles
interndaily.com
AstraZeneca inks China AI research deal for chronic diseases
London (AFP) June 13, 2025 British drugmaker AstraZeneca unveiled on Friday an AI-assisted research partnership with Chinese counterpart CSPC Pharmaceuticals worth up to $5.3 billion to tackle chronic diseases. AstraZeneca, which has a pre-existing collaboration with CSPC, announced earlier this year plans to invest $2.5 billion in China. "This strategic research collaboration underscores our commitment to innovat
The laboratory has entered into a partnership with the CSPC laboratory, which could have a value of up to $5 billion.
The multinational pharmaceutical and biotechnology company AstraZeneca presented on Friday a collaboration of research assisted by artificial intelligence with its Chinese counterpart CSPC Pharmaceuticals, in an agreement valued at 5 billion dollars, says the AFP note. "This strategic research collaboration underlines our commitment to innovation to address chronic diseases that affect [...] The entry AstraZeneca establishes an alliance of resea…
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
